Symposium 28:Programmatic Management of LTBI: Progress and Challenges
In order to accelerate achieving the goal of end TB by 2035, prompt intervention of latent TB infection (LTBI) is one of the new strategies proposed by World Health Organization under estimation of approximately one quarter of global population have LTBI and 5 to 10% among them will become active TB disease in their lifetime. Under the coordination and efforts of global public health policy, medical departments, and research departments, the evolution of new diagnostic tools and treatment regimens is aimed to pursue the highly cost-effectiveness and safe LTBI management. We however still face some clinical challenges, this symposium will bring together researchers and health professionals from various countries to discuss and review current progress and challenges in programmatic management of LTBI. We will stimulate and generate more ideas to promote patient-centered care through discussion.
Time (GMT+8) |
Topic | Speaker | Country / Region |
---|---|---|---|
09:00-09:30 | Completion, safety, and efficacy of rifampicin/rifapentine containing tuberculosis preventive treatment regimens | Prof. Nicholas Winters | Canada |
09:30-10:00 | Real-world experiences on LTBI intervention in people with risk factors | Prof. Yan Lin | China |
10:00-10:30 | The advances of LTBI treatment management: from the prospective of regimen and programmatic management | Prof. Hung-Ling Huang | Taiwan |